PDB: 591 resultsInfo pagesStatus searchChemie searchBIRD

---

1O45	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU84687. Descriptor: N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-3-FORMYL-O-PHOSPHONOTYROSINAMIDE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.8 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O4F	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79073. Descriptor: 1,2,3,4-TETRAHYDROQUINOLIN-8-YL DIHYDROGEN PHOSPHATE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (2 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O4K	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PASBN. Descriptor: BENZYL 2-FORMYLPHENYL HYDROGEN PHOSPHATE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.57 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O43	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82129. Descriptor: PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC, [4-((1Z)-2-(ACETYLAMINO)-3-{[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]AMINO}-3-OXOPROP-1-ENYL)-2-FORMYLPHENYL]ACET IC ACID Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.5 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O49	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU85493. Descriptor: PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC, {4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-PHOSPHONO-PHENOXY}-ACETIC ACID Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.7 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O4G	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH DPI59. Descriptor: HYDROXY(1-NAPHTHYL)METHYLPHOSPHONIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (1.55 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O4M	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH MALONICACID. Descriptor: MALONIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.6 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O4A	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82197. Descriptor: 4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-FORMYL-BENZOIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.5 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O42	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU81843. Descriptor: N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-O-PHOSPHONOTYROSINAMIDE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.7 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O4E	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78299. Descriptor: 2,6-DIFORMYL-4-METHYLPHENYL DIHYDROGEN PHOSPHATE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (2 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O4R	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78783. Descriptor: (PHENYL-PHOSPHONO-METHYL)-PHOSPHONIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.5 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O4B	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU83876. Descriptor: N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-3,4-DIPHOSPHONOPHENYLALANINAMIDE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.85 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O48	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU85053. Descriptor: 5-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-CARBOXYMETHYL-BENZOIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.55 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O4O	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PHENYLPHOSPHATE. Descriptor: PHENYL DIHYDROGEN PHOSPHATE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.7 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O44	Crystal structure of sh2 in complex with ru85052 Descriptor: 2-{4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-CARBOXY-PHENYL}-MALONIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.7 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O4C	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PHOSPHATE. Descriptor: PHOSPHATE ION, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (1.8 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O4I	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PAS219. Descriptor: PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC, cyclohexylmethyl 2-formylphenyl hydrogen (S)-phosphate Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.75 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O41	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78300. Descriptor: 2-FORMYL-6-METHOXYPHENYL DIHYDROGEN PHOSPHATE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.7 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O47	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82209. Descriptor: N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-4-[DIFLUORO(PHOSPHONO)METHYL]PHENYLALANINAMIDE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.8 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O46	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU90395. Descriptor: 2-{4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-METHOXYCARBONYL-PHENYL}-2-FLUORO-MALONIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (2 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1NZL	Crystal Structure of Src SH2 domain bound to doubly phosphorylated peptide PQpYEpYIPI Descriptor: CHLORIDE ION, Doubly phosphorylated peptide ligand (PQpYEpYIPI), TETRAETHYLENE GLYCOL, ... Authors: Lubman, O.Y, Waksman, G. Deposit date: 2003-02-18 Release date: 2003-04-22 Last modified: 2023-11-15 Method: X-RAY DIFFRACTION (1.9 Å) Cite: Structural and Thermodynamic Basis for the Interaction of the Src SH2 domain with the Activated form of the PDGF beta-receptor J.Mol.Biol., 328, 2003
1O4H	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79072. Descriptor: 2-CYANOQUINOLIN-8-YL DIHYDROGEN PHOSPHATE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (2.25 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1O4L	CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH FRAGMENT2. Descriptor: CITRIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC Authors: Lange, G, Loenze, P, Liesum, A. Deposit date: 2003-06-15 Release date: 2004-02-17 Last modified: 2023-08-16 Method: X-RAY DIFFRACTION (1.65 Å) Cite: Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J.Med.Chem., 46, 2003
1OO3	P395S mutant of the p85 regulatory subunit of the N-terminal src homology 2 domain of PI3-Kinase Descriptor: Phosphatidylinositol 3-kinase regulatory alpha subunit Authors: Guenther, U.L, Weyrauch, B, Schaffhausen, B. Deposit date: 2003-03-03 Release date: 2003-03-25 Last modified: 2021-11-10 Method: SOLUTION NMR Cite: Nuclear magnetic resonance structure of the P395S mutant of the N-SH2 domain of the p85 subunit of PI3 kinase: an SH2 domain with altered specificity Biochemistry, 42, 2003
1OO4	P395S mutant of the p85 regulatory subunit of the N-terminal src homology 2 domain of PI3-Kinase complexed to a peptide derived from PDGFr Descriptor: 8-mer peptide from PDGFr, Phosphatidylinositol 3-kinase regulatory alpha subunit Authors: Guenther, U.L, Weyrauch, B, Schaffhausen, B. Deposit date: 2003-03-03 Release date: 2003-03-25 Last modified: 2023-11-15 Method: SOLUTION NMR Cite: Nuclear magnetic resonance structure of the P395S mutant of the N-SH2 domain of the p85 subunit of PI3 kinase: an SH2 domain with altered specificity Biochemistry, 42, 2003

<45678910111213141516171819>